Kallyope links oral obesity combo to 3% weight loss, rejigs pipeline as migraine asset advances

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral prospects to weight loss of 2.9% after 13 weeks of treatment.

The data, which were uploaded to ClinicalTrials.gov and first reported by Endpoints, suggest Kallyope’s cocktail will struggle to compete on weight loss.